Back

Can we avoid randomized clinical trials for new CV drugs? .

26 August 2018 (09:15 - 09:37)
Organised by:
Congress Presentation Part of: Current controversies in clinical trial design Cardiovascular Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Ms Karen Pieper

Thrombosis Research Institute, London (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
Critical issues in endpoint definition.
Professor J. Tijssen (Amsterdam, NL)
Slides Video
Presentation thumbnail
Lost to follow-up in cardiovascular trials.
Associate Professor V. Serebruany (Baltimore, US)
Slides Video
Presentation thumbnail
Current controversies in clinical trial design - Panel discussion.
Video

Access the full session

Session thumbnail
Current controversies in clinical trial design

The Event

Event poster

ESC Congress 2018

26 August 2018 09:15 CET
You may be interested in
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
ESC TV Today
Episode 7: Coronary spasm - Sex differences in heart failure
thumbnail
Congress Session
Challenges in hypertension management

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources